Pharmaceutical company trials and the integrity of medical research [10]

Lancet

Volumn 347, Issue 9015, 1996, Pages 1628-1629

  Tritsmans, L ^a   Briscoe, P ^a   Lemmens, P ^a   Vanden Bussche, G ^a   Harrison, P J ^a   Huston, P ^a   Moher, D ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; NEUROLEPTIC AGENT;

CLINICAL TRIAL; DRUG INDUSTRY; HUMAN; LETTER; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; METHODOLOGY; NOTE; PATIENT SELECTION; PUBLISHING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; PHASE 3 CLINICAL TRIAL;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; PATIENT SELECTION; PUBLISHING; RESEARCH DESIGN; RISPERIDONE; CLINICAL TRIALS, PHASE III;

EID: 0029943426     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91115-0     Document Type: Letter

References (0)